Em implementação
FASE
Número Europeu 2025-523869-22-00
1438-0011 DAREON®-NEC-1
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Detalhes
Destaques